Emerging evidence suggests WISP-1 mediates fibrotic remodelling in multiple organs [25,27,28] and previous studies showed encouraging results when administrating WISP-1-blocking antibodies to treat hepatic fibrosis and pulmonary fibrosis [26,27]. The gene discussed is CCN4; the disease is pulmonary fibrosis.